Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378469 | 0.98 | JAK2 (0.36) | RAB9ANPC1IRAK4JAK2JAK3 | |
| SCHEMBL2378283 | 0.92 | JAK2 (0.35) | RAB9ANPC1JAK2JAK3JAK1 | |
| SCHEMBL2378996 | 0.90 | JAK2 (0.37) | RAB9ANPC1JAK2JAK3JAK1 | |
| SCHEMBL2377584 | 0.88 | CHEK2 (0.36) | RAB9ANPC1IRAK4JAK2JAK3 | |
| SCHEMBL2378303 | 0.87 | NPC1 (0.33) | RAB9ANPC1L3MBTL1 | |
| SCHEMBL2376248 | 0.85 | JAK2 (0.42) | JAK2JAK3JAK1 | |
| SCHEMBL2378019 | 0.85 | CHEK2 (0.35) | RAB9ANPC1IRAK4JAK2JAK3 | |
| SCHEMBL2377057 | 0.85 | JAK2 (0.42) | JAK2JAK3JAK1 | |
| SCHEMBL2378441 | 0.85 | DGAT1 (0.32) | RAB9ANPC1JAK2JAK3JAK1 | |
| SCHEMBL2378164 | 0.85 | CHEK2 (0.39) | JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102232076-A | Pyrrolopyrazinyl urea kinase inhibitors | HOFFMANN LA ROCHE | 2011-11-02 | — | — | CN | disclosed |
| EP-2373653-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010063634-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | RAB9A 2557/4885NPC1 4394/4885IRAK4 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.